

AUSTRALIAN PRODUCT INFORMATION – ONDANSETRON ODT VIATRIS (ONDANSETRON) ORALLY-DISINTEGRATING TABLETS

1 NAME OF THE MEDICINE

Ondansetron

2 & 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM

ONDANSETRON ODT VIATRIS 4 mg and 8 mg tablets contain the following excipients: Microcrystalline cellulose, mannitol, pregelatinised maize starch, crospovidone, aspartame, guar gum, colloidal anhydrous silica, magnesium stearate, sodium lauryl sulphate, Strawberry Guarana 586997 AP0551

ONDANSETRON ODT VIATRIS 4 mg orally disintegrating tablets: White to off-white, round, biconvex, uncoated tablets embossed '4' on one side and 'O' on the other side.

ONDANSETRON ODT VIATRIS 8 mg orally disintegrating tablets: White to off-white, round, biconvex, uncoated tablets embossed '8' on one side and 'O' on the other side.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

4.2 DOSE AND METHOD OF ADMINISTRATION

The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of ondansetron should be flexible in the range of 8 to 32 mg a day and selected as shown below. The lowest effective dose should be used.

The ONDANSETRON ODT VIATRIS orally disintegrating tablet is administered by placing it on top of the tongue where it dissolves within seconds, and is swallowed.

Adults. Emetogenic chemotherapy and radiotherapy For the control of chemotherapy or radiotherapy induced emesis or nausea in adults, two oral doses of 8 mg each at 12 hourly intervals may be given (tablets or orally disintegrating tablets), the first dose being administered two hours prior to chemotherapy or radiotherapy. To protect against delayed emesis after the first 24 hours, ondansetron should be continued orally at a dosage of 8 mg twice daily, for up to five days after a course of treatment.

Use in children. Emetogenic chemotherapy and radiotherapy Experience is currently limited but ondansetron was effective and well tolerated in children over 4 years of age, when given intravenously at a dose of 5 mg/m² over 15 minutes immediately before chemotherapy,

followed by oral therapy at doses of 4 mg twice daily for up to five days. The dose of 5 mg/m² is based on limited data.

Use in the elderly. Emetogenic chemotherapy and radiotherapy Efficacy and tolerance in patients aged over 65 years was similar to that seen in younger adults, indicating no need to alter dosage or route of administration in the elderly.

Impaired renal function. No alteration of daily dosage, frequency of dosing or route of administration is required.

Impaired hepatic function. A study which investigated the effect of hepatic impairment on the pharmacokinetics of ondansetron in 24 subjects showed that the plasma clearance of ondansetron is reduced to about 20% of normal and the serum half-life is significantly prolonged in subjects with severe impairment of hepatic function.

The results in patients with only mildly or moderately impaired hepatic function were less clear. The study showed that in this group the plasma clearance of ondansetron fell to about 50% of that seen in healthy volunteers. Subjects with mild and moderate impairment were not distinguishable from each other for any parameter. This was believed to be partly due to the lack of sensitivity of the Pugh classification system in distinguishing between patients with mild or moderate impairment.

It is recommended that a total daily dose of 8 mg should not be exceeded for patients with moderate or severe hepatic dysfunction. For optimum clinical effect it is recommended that this total daily dose be administered before chemotherapy or radiotherapy.

The severity of the liver disease was assessed according to Pugh's modification of Child's classification (Pugh *et al.*, *Brit. J. Surg.* 1973; 60 (8): 646-649). Patients with a Pugh score of 5 or less were considered to have good hepatic function. A patient with a score of 6 was graded as having mild hepatic impairment, 7 to 9 as moderate hepatic impairment and 10 or more as severe hepatic impairment. The clinical features used in the grading and the weighting system applied are shown in **Table 1**.

Table 1 Grading of hepatic impairment

Clinical and biochemical measurements	Points scored for increasing abnormality		
	1	2	3
Encephalopathy (grade)*	None	1 and 2	3 and 4
Ascites	Absent	Slight	Moderate
Bilirubin (micromol/L)	17.1 – 34.2	34.2 – 51.3	> 51.3
Albumin (g/L)	35	28 – 35	< 28
Prothrombin time (seconds prolonged)	1 – 4	4 – 6	> 6
For primary biliary cirrhosis			
Bilirubin (micromol/L)	17.1 – 68.4	68.4 – 171	> 171

* According to grading of Trey, Burns and Saunders (1966)

Patients with poor sparteine/debrisoquine metabolism. There were no significant differences among poor and extensive debrisoquine categorised metabolisers with regard to ondansetron disposition (area under the curve, total systemic clearance, elimination half-life) following a single 8 mg intravenous dose. The effect of repeated dosing was not investigated, nevertheless dosage adjustments will probably not be required in patients receiving ondansetron by the oral route.

4.3 CONTRAINDICATIONS

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

Hypersensitivity to any component of the preparation (see **4.4 SPECIAL WARNINGS AND PRECAUTIONS**).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Identified precautions

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT₃-receptor antagonists.

Ondansetron prolongs the QT interval in a dose-dependent manner. In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.

Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.

Serotonin syndrome has been described following the concomitant use of ondansetron and other serotonergic drugs (see **4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.

As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

ONDANSETRON ODT VIATRIS orally disintegrating tablets contain aspartame and therefore should be taken with caution in patients with phenylketonuria.

Repeat dosing has not been studied in paediatric patients who experience nausea and/or vomiting despite receiving ondansetron prophylaxis or who continue to experience symptoms after ondansetron treatment.

Myocardial Ischaemia

Cases of myocardial ischaemia have been reported in patients treated with ondansetron. In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron. Patients should be alerted to the signs and symptoms of myocardial ischaemia.

Use in the elderly

No data available.

Paediatric use

No data available.

Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, alfentanil, furosemide, tramadol or propofol.

Ondansetron is metabolised by multiple hepatic cytochrome P450 drug enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.

Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities (see **4.4 SPECIAL WARNINGS AND PRECAUTIONS**).

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.

Following a single 8 mg tablet dose of ondansetron, a three to fourfold decrease in the systemic exposure has been seen in adult epileptic subjects maintained on chronic doses of carbamazepine (n = 8) or phenytoin (n = 8) and not receiving chemotherapy. The effect of these enzyme inducing agents on intravenous ondansetron has not been assessed, but the absence of any first pass effects would be expected to result in a smaller change in exposure than seen following oral dosing.

Due to the limited efficacy data in subjects on antiepileptics and the many variables that may influence exposure and response, the clinical significance of this drug interaction in cancer patients receiving chemotherapy is not known.

Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.

Serotonergic Drugs (e.g., SSRIs and SNRIs)

Serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) has been described following the concomitant use of ondansetron and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) (see **4.4 SPECIAL WARNINGS AND PRECAUTIONS**).

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

Oral doses of ondansetron up to 15 mg/kg/day in rats had no effect on male or female fertility.

Women of childbearing potential should consider the use of contraception.

Use in pregnancy – Pregnancy Category B1

Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy. The available epidemiological studies on cardiac malformations show conflicting results. Animal studies does not indicate direct or indirect harmful effects with respect to reproductive toxicity. Ondansetron should not be used during the first trimester of pregnancy.

Use in lactation.

Tests have shown that ondansetron is excreted in the breast milk of rats. It is therefore recommended that mothers receiving ondansetron should not breastfeed their babies.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (greater than or equal to 1/10), common (greater than or equal to 1/100 and < 1/10), uncommon (greater than or equal to 1/1,000 and < 1/100), rare (greater than or equal to 1/10,000 and < 1/1,000) and very rare (< 1/10,000), including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare and very rare events were generally determined from postmarketing spontaneous data.

The following frequencies are estimated at the standard recommended doses of ondansetron according to indication and formulation.

Immune system disorders.

Rare: immediate hypersensitivity reactions, sometimes severe, including anaphylaxis.

Nervous system disorders.

Very common: headache.

Uncommon: seizures, movement disorders (including extrapyramidal reactions such as oculogyric crisis, dystonic reactions and dyskinesia have been observed without definitive evidence of persistent clinical sequelae).

Eye disorders.

Rare: transient visual disturbances (e.g. blurred vision) predominantly during intravenous administration.

Very rare: transient blindness predominantly during intravenous administration.

The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.

Cardiac disorders.

Uncommon: arrhythmias, chest pain with or without ST segment depression, bradycardia.

Rare: QTc prolongation (including Torsade de Pointes)

Unknown: Myocardial ischaemia

Vascular disorders.

Common: sensation of warmth or flushing.

Uncommon: hypotension.

Respiratory, thoracic and mediastinal disorders.

Uncommon: hiccups.

Gastrointestinal disorders.

Common: constipation, xerostomia.

Hepatobiliary disorders.

Uncommon: asymptomatic increases in liver function tests#.

#These events were observed commonly in patients receiving chemotherapy with cisplatin.

Skin and subcutaneous tissue disorders.

Very rare: toxic skin eruption, including toxic epidermal necrolysis.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

Symptoms. Little is known at present about overdosage with ondansetron, however, a limited number of patients have received overdoses. Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second degree AV block. In all instances, the events resolved completely.

Ondansetron prolongs QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.

Cases consistent with serotonin syndrome have been reported in young children following oral overdose.

Treatment. There is no specific antidote for ondansetron, therefore in cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action

Ondansetron is a potent, highly selective 5HT₃-receptor antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine, initiating a vomiting reflex by activating vagal afferents via 5HT₃-receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is due to antagonism of 5HT₃-receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in postoperative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting. In psychomotor testing, ondansetron does not impair performance or cause sedation. Ondansetron does not alter plasma prolactin concentrations.

A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. The clinical relevance of this finding is uncertain.

Clinical trials

Chemotherapy and radiotherapy induced nausea and vomiting. Adult studies.

Highly emetogenic chemotherapy. In a double blind, randomised study 152 patients were given ondansetron 8 mg intravenously as a single dose and 173 patients were given 32 mg intravenously as a single dose 30 minutes prior to cisplatin (greater than or equal to 50 mg/m²). No significant difference in terms of emesis control or grade of nausea was demonstrated between 8 mg or 32 mg.

However, in some studies conducted in patients receiving medium (50 to 90 mg/m²) or high doses (greater than or equal to 100 mg/m²) of cisplatin chemotherapy, the 32 mg single dose has demonstrated a statistically significant superiority over the 8 mg single dose with regard to control of emesis (see **4.2 DOSE AND METHOD OF ADMINISTRATION**).

In a double blind, randomised, crossover trial, 103 chemotherapy naive patients scheduled to receive cisplatin (50 to 120 mg/m²) chemotherapy were recruited. 91 patients completed both courses of ondansetron 0.15 mg/kg (8 mg) intravenously (three doses) with or without dexamethasone 20 mg intravenously. The combination of ondansetron and dexamethasone was shown to be significantly superior to ondansetron alone.

In a randomised, double blind parallel group study, 420 patients were randomised to receive either a ondansetron 16 mg suppository prior to cisplatin chemotherapy (greater than or equal to 50 mg/m²) on day 1 followed by a ondansetron 16 mg suppository once daily for a further two days, or ondansetron 8 mg intravenously prior to cisplatin chemotherapy followed by ondansetron 8 mg orally twice daily for a further two days. Results from the primary efficacy analysis (i.e. less than or equal to two emetic episodes on day 1) show that an ondansetron suppository and combined ondansetron intravenous and oral regimens are equivalent.

However, results from the secondary efficacy analyses (e.g. number of emetic episodes on day 1, the worst day of days 1 to 3 and overall of days 1 to 3) showed that the ondansetron suppository was less effective.

Patients on a combined ondansetron intravenous and oral regimen remained free of emesis for significantly longer than patients receiving ondansetron suppository.

In a randomised double blind, parallel group study 542 patients were randomised to receive either ondansetron tablets (3 x 8 mg) plus dexamethasone capsules (2 x 6 mg), or intravenous ondansetron 8 mg plus intravenous dexamethasone 20 mg, prior to cisplatin infusion. Ondansetron 24 mg administered orally was as effective as ondansetron 8 mg given intravenously in controlling acute emesis and nausea induced by cisplatin chemotherapy. One ondansetron 24 mg tablet has been shown to be bioequivalent to three ondansetron 8 mg tablets.

There are no studies on the use of suppositories in radiation induced nausea and vomiting.

Emetogenic chemotherapy. In a double blind, parallel group study 82 patients were randomised to either ondansetron 8 mg intravenously prior to cyclophosphamide (greater than or equal to 500 mg/m²) based chemotherapy (doxorubicin or epirubicin greater than or equal to 40 mg/m²) followed by 8 mg orally three times a day for three to five days or metoclopramide 60 mg intravenously prior to chemotherapy followed by 20 mg orally three times a day for three to five days. Ondansetron was shown to be significantly superior to metoclopramide.

In a randomised, single blind study, ondansetron 8 mg orally twice daily in 155 patients was compared with ondansetron 8 mg orally three times daily in 153 patients for three to five days following chemotherapy. Ondansetron 8 mg intravenously was given prior to cyclophosphamide (greater than or equal to 500 mg/m²) based chemotherapy (doxorubicin or epirubicin > 40 mg/m²) on day 1. Ondansetron 8 mg given orally twice daily was as effective as ondansetron 8 mg given orally three times daily.

In a randomised double blind parallel group study, 406 patients were randomised to receive either an ondansetron 16 mg suppository once daily for three days or ondansetron 8 mg orally twice daily for three days. The first administration of the suppository and tablet began two hours and one to two hours respectively prior to cyclophosphamide chemotherapy (greater than or equal to 500 mg/m²) on day 1. Results from the primary efficacy analysis (less than or equal to two emetic episodes on the worst day of days 1 to 3) show that the ondansetron suppository treatment is equivalent to the ondansetron oral treatment. The ondansetron suppository was less effective than ondansetron oral treatment for a number of other secondary efficacy criteria (complete control of emesis on the worst day of days 1 to 3, total number of emetic episodes days 1 to 3 and number of emetic episodes on worst day of days 1 to 3).

Paediatric studies. Three open label, uncontrolled, noncomparative studies have been performed with 182 patients aged 4 to 18 years with cancer who were given a variety of cisplatin or noncisplatin regimens. In these trials an initial intravenous dose of ondansetron was followed by oral administration of ondansetron. In these studies, 58% of the 170 evaluable patients had no emetic episodes on day 1.

5.2 PHARMACOKINETIC PROPERTIES

Absorption, Distribution, Metabolism and Excretion

Following oral dosing with ondansetron, peak plasma concentrations are achieved in approximately 1.5 hours. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first-pass metabolism at higher doses. The absolute bioavailability of the ondansetron tablet is approximately 60% (range 36 to 112%).

The plasma protein binding is 70 to 76%. The volume of distribution is 1.8 L/kg.

Ondansetron is extensively metabolised in humans, with approximately 5% of a radiolabelled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacological activity, these are not found in plasma concentrations likely to significantly contribute to the biological activity of ondansetron. Ondansetron is a substrate for multiple human hepatic cytochrome P450 enzymes including CYP1A2, CYP2D6 and CYP3A4. This multiplicity of metabolic enzymes capable of metabolising ondansetron means that inhibition or loss of one enzyme (e.g. CYP2D6 genetic deficiency) results in little change in overall rates of ondansetron elimination.

The terminal elimination half-life of ondansetron after oral dosing is 4.1 to 11.6 hours. The half-life may be prolonged in the elderly. In patients with severe hepatic impairment, systemic clearance is markedly reduced with prolonged elimination half-lives (15 to 32 hours) and an oral bioavailability approaching 100% because of reduced pre-systemic metabolism.

In a study of 21 children aged 3 to 12 years receiving elective surgery with general anaesthesia, the clearance and volume of distribution of ondansetron following a single intravenous dose of 2 mg (3 to 7 years old) or 4 mg (8 to 12 years old) were reduced. The size of the change was age related with clearance falling from about 300 mL/minute at 12 years of age to 100 mL/minute at 3 years. Volume of distribution fell from about 75 L at 12 years to 17 L at 3 years.

The clinical safety of ondansetron in children under 2 years has not been established. Increased incidence of mortality with no specific target organ toxicity has been observed in young rats with immature drug metabolising enzymes.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Ondansetron did not induce mutations in *Salmonella typhimurium*, *Escherichia coli* or Chinese hamster ovary cells in the presence or absence of metabolic activation, and showed no potential for causing chromosomal damage *in vitro* in peripheral human lymphocytes or *in vivo* in a mouse micronucleus assay. No evidence for DNA damage was observed with ondansetron in a yeast mitotic gene conversion assay.

Carcinogenicity

No evidence for carcinogenic activity was found in two year studies at ondansetron doses up to 10 mg/kg/day by gavage in rats or up to 30 mg/kg/day via drinking water in mice.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Refer to Section 2 - Qualitative and quantitative composition.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

6.5 NATURE AND CONTENTS OF CONTAINER

ONDANSETRON ODT VIATRIS 4 mg orally disintegrating tablets: White to off-white, round, biconvex, uncoated tablets embossed '4' on one side and 'O' on the other side; Packs of 4, 6 or 10 (foil blister pack)

ONDANSETRON ODT VIATRIS 8 mg orally disintegrating tablets: White to off-white, round, biconvex, uncoated tablets embossed '8' on one side and 'O' on the other side; Packs of 4, 6 or 10 (foil blister pack)


6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Ondansetron is a white to off white powder with a melting point of approximately 230°C. It is insoluble in water. It is soluble in chloroform and acetic acid. The pKa of ondansetron is 10.4 at 30°C (Diluent: water and methanol in the ratio of 35:65).

Chemical structure



CAS number

99614-02-5 (ondansetron)

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

Dr Reddy's Laboratories Australia Pty Ltd

Suite 3.03, Level 3, 390 St Kilda Road

Melbourne VIC 3004

Tel: (03) 8394 1888

Website: <http://www.drreddys.com/australia/>

Distributor

Alphapharm Pty Ltd trading as Viatris

Level 1, 30 The Bond

30-34 Hickson Road

Millers Point, NSW 2000

9 DATE OF FIRST APPROVAL

26 October 2017

10 DATE OF REVISION

26 May 2023

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.6	Women of childbearing potential should consider the use of contraception.
4.4 & 4.8	Myocardial ischaemia